Advertisements



Piper says Ubrelvy prescription trajectory bodes well for Biohaven"s rimegepant

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 14th, 2020

Talk with Biohaven CEO gives Mizuho continued confidence in rimegepant

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 10th, 2020

Biohaven shares should not be down this much on study miss, says Piper Sandler

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 10th, 2020

Biohaven now has second, complementary CGRP product, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 17th, 2019

Biohaven Pharmaceutical presents expanded data from study of rimegepant

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: worldSource: nytSep 9th, 2019

Biohaven update on rimegepant should be well received, says Goldman Sachs

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 4th, 2019

Biohaven rallies after update on rimegepant new drug application

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 4th, 2019

Piper Jaffray encouraged by GW Pharmaceutical"s Epidiolex trajectory

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 29th, 2019

Biohaven Pharmaceutical"s rimegepant Zydis for migraine featured in The Lancet

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 15th, 2019

Biohaven Pharmaceutical"s rimegepant featured in 16 presentations at AHS meeting

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 11th, 2019

Biohaven reports "positive" results from Phase 3 rimegepant clinical trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 10th, 2019

Biohaven Pharmaceutical enrolls first patient in Phase 2 rimegepant trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 1st, 2019

The 5 Most Expensive Drugs In US: What You Should Know

The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers. Prices of drugs are staggeringly high in the U.S. when compared to other developed countries such as Japan and in Europe. read more.....»»

Category: blogSource: benzingaJun 23rd, 2019

Biohaven reports new safety and efficacy data of rimegepant in migraine

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 8th, 2019

Biohaven Pharmaceutical price target raised to $100 from $75 at Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 8th, 2019

PolarityTE SkinTE sales trajectory remains positive, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 18th, 2019

Biohaven priority review purchase could bring 2019 approval, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 18th, 2019

Biohaven secures FDA PRV to use with NDA submission of rimegepant Zydis ODT

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 18th, 2019

Biohaven Pharmaceutical completes pre-NDA meeting with FDA for rimegepant

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 13th, 2019

Biohaven announces key secondary outcome measures from rimegepant Phase 3 trials

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 23rd, 2018

Piper calls Biohaven "rare high quality, yet undervalued" biotech

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 8th, 2018